At Medivation, Dr. Hung identified, in-licensed and developed talazoparib, a potentially best-in-class PARP inhibitor, which was approved by the FDA in October 2018, and the immune-oncology agent, pidilizumab, which demonstrated robust effects in Phase 2 studies and is now a promising Phase 3-ready asset.
Between Medivation and founding Nuvation Bio, Dr. Hung served for 10 months as Chief Executive Officer at Axovant Sciences before tendering his resignation. Prior to founding Medivation, he served as President and Chief Executive Officer of ProDuct Health, Inc., a venture-backed startup medical device company founded in 1998 that developed, manufactured and commercialized a breast microcatheter – that he invented – for breast cancer risk assessment. ProDuct Health was acquired in 2001 for $168 million by Cytyc Corporation.
Dr. Hung received an A.B. summa cum laude in biology from Harvard College and an M.D. Alpha Omega Alpha from the University of California, San Francisco, School of Medicine. He completed simultaneous clinical fellowships in hematology, oncology and transfusion medicine as well as two basic science research fellowships in molecular biology at the University of California, San Francisco, School of Medicine.